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Echocardiography as an outcome measure in scleroderma-related
pulmonary arterial hypertension: a systematic literature analysis
by the EPOSS group
Abstract
OBJECTIVE: To assess the validation status of echocardiography with continuous Doppler
(echo-Doppler) as an outcome measure in pulmonary arterial hypertension associated with systemic
sclerosis (PAH-SSc). METHODS: Structured literature review on full-text English articles was
performed using the PubMed and Cochrane databases. Assessment of validation of echo-Doppler was
based on the OMERACT filter criteria with the domains truth (face, content, construct, and criterion
validity), discrimination, and feasibility. RESULTS: Out of 35 studies eligible for analysis, only 5
included well defined PAH-SSc subgroups (World Health Organization criteria). Echo was considered
as having face validity based on expert opinion and high number of studies using echo for evaluation of
patients with SSc. Echo was considered partially validated with respect to criterion validity based on
significant correlations between echo measures and right-heart catheterization in patients with SSc at
risk of PAH/PH. However, echo was found to lack specificity (lack of content validity), since
measurements of echo pulmonary pressure may be influenced by left-heart disease and interstitial lung
disease. Data from general populations of patients with scleroderma indicate that evaluation of
pulmonary artery pressure by echo might not be available in all PAH-SSc patients because of technical
factors. No studies enabling evaluation of the discriminant capacity over time and treatment of echo in
PAH-SSc could be identified. CONCLUSION: Further studies are needed to fully validate
echo-Doppler as an outcome measure in PAH-SSc. These studies would include cross-sectional analysis
of baseline measures and longitudinal data of placebo and verum groups in randomized controlled trials
of patients with PAH-SSc.
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Aim: To assess the validation status of echo-Doppler as an outcome measure in pulmonary 
arterial hypertension associated with systemic sclerosis (PAH-SSc).  
Methods: Structured literature review on full-text English articles was performed using the 
PubMed and Cochrane databases. The assessment of validation of echo-Doppler was based on 
the “OMERACT filter” criteria with the domains truth (face, content, construct, and criterion 
validity), discrimination, and feasibility.      
Results: Out of 35 studies eligible for analysis, only 5 included well-defined (according to the 
World Health Organization criteria) PAH-SSc subgroups. Echo was considered as having face 
validity based on expert opinion and high number of studies using echo for evaluation of SSc 
patients. Echo was considered partially validated with respect to criterion validity based on 
significant correlations between echo measures and right heart catheterization in SSc patients 
being at risk of PAH/PH. However, echo was found to lack specificity (lack of content 
validity), since measurements of echo pulmonary pressure may be influenced by left heart 
disease and interstitial lung disease. Data from general populations of scleroderma patients 
indicate that evaluation of pulmonary artery pressure by echo might not be available in all 
PAH-SSc patients because of technical factors. No studies enabling evaluation of the 
discriminant capacity over time and treatment of echo in PAH-SSc could be identified. 
Conclusions: Further studies are needed to fully validate echo-Doppler as an outcome 
measure in PAH-SSc. These studies include cross-sectional analysis of baseline measures and 
longitudinal data of placebo and verum groups in randomized controlled trials of patients with 
PAH-SSc.  
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Abbreviations used in the text 
 
CTD Connective tissue disease 
echo-Doppler Echocardiography with continuous Doppler 
EPOSS Expert Panel on Outcomes Measures in PAH 
related to Systemic Sclerosis 
FVC Forced vital Capacity 
HRCT High resolution computed tomography 
NYHA New York Heart Association 
OMERACT The Outcome Measure in Rheumatology 
PAH Pulmonary arterial hypertension 
PAH-SSc Pulmonary arterial hypertension associated with 
systemic sclerosis 
PH-SSc Pulmonary hypertension associated with systemic 
sclerosis 
PAP Pulmonary artery pressure 
PASP Pulmonary artery systolic pressure 
PH Pulmonary hypertension 
RCT Randomized controlled trial 
RHC Right heart catheterization 
SSc Systemic sclerosis 
VTR Velocity of tricuspid regurgitation 











Pulmonary arterial hypertension (PAH) associated with systemic sclerosis (scleroderma, SSc) 
is one of the most frequent causes of death in SSc patients. PAH develops on the basis of 
obstructive proliferative vasculopathy of small and medium-sized pulmonary arteries. In the 
setting of SSc, other causes than primary pulmonary vasculopathy may also lead to an 
increase in pulmonary artery pressure (PAP). Indeed, significant lung disease, which might 
lead to pulmonary hypertension (PH) due to hypoxemia, was found in up to 30-75% of SSc 
patients with elevated PAP [1-2]. Left heart dysfunction, which might cause 
postcapillary/venous PH, was found in up to 13%-19% of SSc patients suspected of having 
PAH [3-4]. 
So far only intravenous epoprostenol has been proven to be beneficial in a randomized 
controlled trial (RCT) exclusively in PAH-SSc patients [5]. In contrast, the other therapies 
were investigated in more general PAH populations, where PAH-SSc contributed 
approximately a quarter of patients. Although numbers were always small and statistical 
power calculations may have confounded the SSc-specific results, post-hoc analyses of these 
studies showed that the PAH-SSc subgroup was usually less responsive than patients with 
idiopathic PAH  [6]. Thus, there is an urgent need for clinical studies aimed at evaluation of 
new therapeutics specifically in PAH-SSc patients. 
Since appropriate outcome measures are of key importance for the correct evaluation of   
clinical trials, the OMERACT (Outcome Measures in Rheumatology Clinical Trials) 
consensus group has developed a set of criteria for the validation of endpoints in rheumatic 
diseases. These criteria are known as the “OMERACT filter” and include: truth (face, content, 
construct, and criterion validity), discrimination (reliability/reproducibility and sensitivity to 
change), and feasibility [7]. These OMERACT criteria should be fulfilled before a specific 
outcome measure is fully validated and recommended for use in clinical trials. 
Among 11 measures identified by a recent expert panel on outcome measures in PAH-
SSc (EPOSS) utilizing a Delphi process among 74 interdisciplinary experts [8], only right 
heart catheterization (RHC) has so far been considered validated according to the 
“OMERACT filter criteria” and therefore judged “ready for use in clinical trials” [9]. 
However, RHC is often not feasible for repeated measures due to its invasiveness. 
Echocardiography including assessment of pulmonary arterial pressures by continuous 
Doppler (echo-Doppler) is another endpoint indicated for consideration by the EPOSS group.  
However, echo requires full validation before it can be recommended for clinical trials in 
PAH-SSc. The aim of the present study was therefore to assess the current status of validation 
of echo in PAH-SSc according to the OMERACT criteria using a systematic literature search. 
The identification of specific aspects of echo that need further validation in PAH-SSc is the 






Systematic literature review 
Studies in which echo was used for the evaluation of patients with PAH/PH-SSc were 
searched in PubMed and Cochrane Controlled Trial Register databases using combinations of 
predefined key words.  The key words used were “systemic sclerosis OR scleroderma OR 
CREST” AND “pulmonary arterial hypertension OR pulmonary hypertension” AND 
“echocardiography OR echo”. To identify other relevant articles, references of the retrieved 
papers and most recent review articles published within the last two years were analyzed. In 
addition, the “related article” tool in PubMed was used. All original studies published 
between 1966 and 15th of January 2008 were selected if they involved ≥ 5 PAH/PH-SSc 
patients. Abstracts or congress reports were not included. Studies with mixed populations of 
PAH patients or patients with different connective tissue diseases were eligible if the subset of 
patients with SSc was separately analyzed, or if > 45% of the patients in the study had SSc. 
The literature analysis was limited to studies published in English and those pertaining to 
humans and adults only.  
Studies were excluded, if they were not an original study, if by definition only patients with 
other forms of PH than PAH were analyzed, if ≥ 55% of patients had other diseases than SSc, 
and if the studies did not include a separate analysis of SSc patients. Studies including < 5 
PAH/PH-SSc patients and those for which there was no information given as to whether any 
PAH/PH-SSc patients were analyzed, were also excluded. Studies concerning exercise echo 
were also not considered for the analysis, because exercise echo was not part of the core set 
recommended by the EPOSS group after the Delphi exercise [8]. 
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The systematic literature search and the analysis of retrieved documents were performed 
independently by two trained reviewers (OKB, JA). If differences in the judgment occurred, 
they were solved by discussion. 
 
Quality evaluation of identified manuscripts according to the methodological quality 
and level of evidence 
The quality of studies fulfilling our inclusion criteria was rated by using the impact factor of 
the journal in which the study was published (ISI Journal Citation Reports 2006) and by the 
Jadad scale [10]. The Jadad scale contains 2 questions to determine appropriate randomisation 
and study masking and 1 question evaluating the reporting of withdrawals and dropouts. Each 
question requires a yes or no response. Five total points can be awarded with a higher score 
indicating superior quality. 
The level of evidence was assessed according to established criteria based on study design 
using a hierarchy of evidence in descending order according to qualities [11].  In brief, meta-
analyses of RCTs were considered the highest level of evidence (1a), followed by RCTs (1b), 
non-randomized controlled studies (2a), quasi-experimental studies (2b), descriptive studies 
(3) and expert committee reports or opinions (4).  
  
Quality evaluation of identified manuscripts according to the definition of pulmonary 
hypertension 
Because this analysis aimed to look at the validation of echo for pulmonary arterial 
hypertension, and because other forms of pulmonary hypertension have different 
pathophysiologies, clinical courses and clinical presentations, we also rated the respective 
studies according to their definition of PAH. The criteria for this quality assessment are 
summarized in Table 1. 
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Based on the tests used for the diagnosis of PAH/PH in the respective studies, the following 
rating was applied: PAH/PH confirmed by RHC (mean PAP higher than 25 mmHg at rest 
and/or higher than 30 mmHg with exercise per WHO definition), was assigned category A; 
PAH/PH assessed by echo with pulmonary artery systolic pressure PASP ≥ 45 mmHg, which 
has 97% specificity versus RHC [13], or pulmonary artery systolic pressure (PASP) > 30 
mmHg by RHC was assigned category B; PAH/PH assessed by echo with 45 mmHg > 
PASP/tricuspid gradient ≥ 35 mmHg, was assigned category C, and all other definitions were 
considered category D. 
In addition, studies were analyzed regarding whether clinically significant interstitial lung 
disease and postcapillary pulmonary hypertension/left heart disease were excluded. Interstitial 
lung disease and left heart disease are considered the most frequent causes of pulmonary 
hypertension other than PAH in SSc. Interstitial lung disease was considered clinically 
significant when restrictive ventilatory defects and/or advanced radiological changes were 
present. Postcapillary pulmonary hypertension was judged based on the wedge pressure 
higher than 15 mmHg on right heart catheterization. Accordingly, studies in which the 
definition of PAH included these exclusions were assigned category 1, while all other studies 
were considered category 2.  
 
Application of the OMERACT filter 
To assess the current status of validation of echo, the OMERACT criteria were used. These 
include: truth (face, content, construct, and criterion validity), discrimination 
(reliability/reproducibility and sensitivity to change), and feasibility [7,9]. Definitions of the 
OMERACT criteria are given in Table 2.    
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The OMERCT criteria were applied on the manuscripts retrieved from the systematic 
literature review. For the final assessment of validation, the quality of the manuscript was 
taken into consideration (see also Table 1): 
Echo was considered valid (V) or not valid (NV) only if high quality studies were available 
with a definition of PAH according to the WHO criteria and if severe interstitial lung disease 
and post-capillary pulmonary hypertension/left heart disease were excluded. This corresponds 
to the “A1” level of the quality assessment as defined above.  
Echo was considered partially validated (PV) if lower quality studies indicated that echo was 
valid. “Lower quality studies” were defined as all studies with a quality assessment below A1. 
These strict criteria were used because these studies might include patients with forms of PH 
other than PAH (e.g. associated with left heart disease, interstitial fibrosis) and a number of 
false positives (PAH not confirmed by RHC). This is relevant for the assessment of outcome 
measures because forms of PH other than PAH have a different pathogenesis, disease 
presentation, disease symptoms and prognosis than patients with PAH. 
Validation status of echo was considered unclear/possibly not valid (U), if “lower quality 
studies” indicated that echo was not valid. Again, lower quality studies were defined as 
studies with a quality assessment below A1.  
Moreover, validation of echo with respect to the sensitivity to change over time required 
longitudinal studies for which parallel data on RHC and echo at two different time points 
were available. Validation of sensitivity to change over treatment required in addition data 
from RCT. 
 
The application of the OMERACT criteria was discussed at three face-to-face meetings of the 
EPOSS steering committee. If there was disagreement on the status of validation, it was 
solved by discussion. 
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RESULTS   
 
Results of the systematic literature search  
Out of 124 articles identified, 87 were excluded based on predefined inclusion/exclusion 
criteria, two studies could not be retrieved for full text review, and 35/124 articles were 
included for further analysis [references 1-4,12-42]. The search strategy of the systematic 
literature research including reasons for exclusions is presented in Figure  1.  
 
Quality assessment of retrieved articles 
 
The 35 retrieved studies were next evaluated according to their level of quality. The results of 
the quality assessment are summarized in Table. Only 5 (14%) studies included well-defined 
PAH-SSc subgroups according to the WHO criteria (quality level A1). Five other studies 
involved patients with PAH/PH diagnosed with RHC, but without excluding lung fibrosis or 
left heart disease (quality level A2). One study reported subgroup analyses corresponding to 
A1 or A2 quality levels [12]. The remaining 25 studies corresponded to lower quality levels: 3 
studies were classified as B2, 13 studies as C2, 9 studies as D2, and one study included 
subgroup analyses of patients classified as C2 or D2 [42]. 
No RCTs fulfilling the inclusion criteria could be identified. Four uncontrolled studies [21-23, 
30] represented level of evidence 2b, while the remaining studies were classified as level of 
evidence 3. The impact factor of the identified studies varied from 0 to 7.421 (mean 3.39).  
 
Status of validation according to the OMERACT criteria  
The current status of validation of echo according to the OMERACT criteria and based on the 




1. Face validity 
Echocardiography was selected by the experts during the recent Delphi study [8] as an 
appropriate measure for the evaluation of PAP, heart structure and function in PAH-SSc 
patients. Thus, by definition, it was considered credible (having face validity). 
 
2. Content validity 
Several studies indicated that echo does not differentiate between different forms of PH 
associated with SSc and is thus not specific for PAH-SSc. Accordingly, left heart 
disease/postcapillary PH were found in up to 19% of SSc patients with increased tricuspid 
velocity (> 2.5 m/s) and in up to 13% of SSc patients considered at high risk of PAH/PH by 
clinical evaluation including echo examination, radiographic studies and lung function tests 
[3-4]. 
Several studies including SSc patients with and without PAH/PH revealed significant 
associations between higher PASP/tricuspid gradient and the presence of interstitial lung 
disease, as evaluated by lung function tests [13, 15, 26-27], or high resolution computed 
tomography (HRCT) of the lungs [1-2, 23, 24]. Significant lung disease (defined by TLC < 
70-80%, and/or diffuse interstitial fibrosis/alveolitis by HRCT) was found in up to 30 - 75% 
of SSc patients with elevated PAP [1,2].  
Thus, it can be anticipated that measurements of PASP by echo-Doppler might reflect the 
presence of interstitial lung disease or left heart disease and not only the pulmonary 
vasculopathy underlying true PAH.  
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Another aspect of content validity is whether the outcome measure of interest covers the 
whole spectrum of disease severity. Denton et al looked at a broad range of PAH/PH patients 
[34]. The range of PAP by RHC in the 6 patients with PAH/PH and no tricuspid regurgitation 
was similar (30-80 mmHg) to that seen in the 15 patients with PAH/PH in whom echo-
Doppler measurement revealed increased PAP (34-109 mmHg), indicating that even in 
patients with moderate/severe PAH/PH, tricuspid regurgitation might not be present. 
 
Taken together, these results show that echo is not specific for PAH and thus does not fulfill 
this aspect of the content validity criterion of the OMERACT filter. The highest quality level 
of studies evaluated for this criterion was A1 [4]. Content validity according to the 
OMERACT filter was therefore rated as “not valid” by the expert group.   
 
3. Criterion validity 
Sensitivity and specificity of echo versus RHC 
The sensitivity of echo-Doppler for identification of SSc patients with PAH/PH ranged from 
39% to 100%, and its specificity from 42% to 97% in comparison with RHC as the “gold 
standard” measure. Sensitivity and specificity depended strongly on the definition of PAH/PH 
by echo and the population of SSc patients [1,12,34,41]. The specificity of echo increased 
with the higher PASP thresholds, reaching 97% for PASP/tricuspid gradient ≥ 45 mmHg. 
Opposite, the sensitivity was highest when the lower cut-off values were used being 90% in 
SSc patients with PASP > 30 mmHg [12,34]. Thus, there is an inverse relationship between 
specificity and sensitivity of echo in identifying patients with PAH/PH-SSc.  
Of note, the majority of studies comparing echo with RHC used in their definition of PAH/PH 
a combination of tricuspid gradient/PASP and, particularly if PASP was not measurable or 
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suggestive of PAH/PH, evaluation of right heart dimensions and function and/or clinical 
assessment including evaluation of dyspnea, pulmonary function tests and/or  chest x rays.  
 
Correlation of parameters measured by echo with PAP measured by RHC 
Three studies involving SSc patients considered to be at high risk of PAH/PH, including those 
with significant interstitial lung disease, showed significant correlations between PASP 
(tricuspid gradient) measured by echo-Doppler and PASP/mean PAP measured by RHC. 
However, r-values were only low to moderate (r2 = 0.5 for PASP and r2 = 0.5 for mPAP, 
respectively) [1,12,34]. Similarly, a study by Murata et al. including 77 patients with 
connective tissue diseases (CTD) of whom 55% were SSc patients showed significant 
correlation between PASP by echo and by direct measurement during RHC (p < 0.01) [40]. 
Depending on the diagnostic criteria, the presence of pulmonary fibrosis by HRCT or 
pulmonary function test was reported in 38% to 75% of patients evaluated in these studies.  
Another study compared the right ventricular myocardial performance index also known as 
Tei index, which is calculated based on echo measurements (the isovolumic contraction time 
and isovolumic relaxation time divided by the ejection time) and RHC measures in a group of 
35 SSc patients with elevated PASP≥35 mmHg, of whom 28 patients had mPAP by RHC 
consistent with the WHO definition of PAH. The right ventricular Tei index significantly 
correlated with the mean PAP by RHC at low r-values (r2 = 0.21, p = 0.01), but not with the 
pulmonary vascular resistance measured during catheterization (r2 = 0.11, p = 0.08). Similarly 
to the two previous studies, patients with interstitial lung disease were also included [17].  
 
Taken together, echo showed - depending on the cut-off value for PASP - an acceptable 
sensitivity and specificity and a significant, but rather weak correlation with right heart 
catheterization. The highest quality level of studies evaluated for sensitivity/specificity and 
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correlation of echo with RHC was A2. The criterion validity was therefore rated “partially 
validated”.  
 
4. Construct validity 
. 
Association with survival/mortality 
Only one study including SSc patients with PAH defined according to the WHO criteria (A1) 
was identified and showed that the presence of pericardial effusion is associated with higher 
number of deaths in PAH-SSc (hazard ratio = 2.35, 95%CI: 1.06 - 5.2, p = 0.04) [19]. The 
presence of pericardial effusion of any size (odds ratio = 10.7, p = 0.001) or significant 
pericardial effusion were also associated with higher mortality in the general SSc population 
[15, 36, 42]. 
Another retrospective, case-control study involving 206 patients with limited cutaneous SSc 
showed that the presence of PH (PASP > 30mmHg by echo in combination with clinical 
symptoms) was associated with lower survival (50% at 2 years and 10% at 5 years) in 
comparison with well matched controls without PH (88% and 80%, respectively) [28]. 
In the study by McGregor et al., high PASP (> 60 mmHg) by echo was associated with higher 
mortality in the overall population of SSc patients with PH (PASP > 30 mmHg by echo), in 
SSc patients with isolated PH (PH without significant lung disease by LFTs/HRCT) and in 
those with PH and lung disease. The risk of death in the whole PH population increased 
significantly (hazard ratio = 3.6; 95%CI: 1.42-9.15) for PASP > 60mmHg. The 2-year 
mortality in SSc patients with isolated PH was 8%, 33% and 67%, and in those with PH and 
lung disease 0%, 15%, and 67%, for PASP < 30 mmHg, 30-60 mmHg and > 60 mmHg, 
respectively. In the overall SSc population (with and without PAH/PH), high initial PASP (> 
60mmHg) by echo was an independent risk factor for mortality (by multivariate analysis) 
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[31]. Similarly, the presence of PH by echo was associated with lower survival in the overall 
SSc population combining those with and without PH (odds ratio = 9.8, p = 0.002 for PH 
versus those without PH) in the study by Simeon [36], and in early diffuse SSc patients 
(PASP ≥ 45 mmHg, p = 0.001 versus those without PH) in the study by Trad [22].  
 
Associations with dyspnea/functional capacity, exercise tolerance (six minute walk test 
(6MWT), oxyhemoglobin desaturation after exercise (ΔO2Sat), and maximal oxygen 
consumption during exercise testing) 
In 67 SSc patients with and without PH, in whom interstitial lung disease had been excluded 
(by HRCT), greater dyspnea (by NYHA classification) appeared as an independent factor 
associated with PH defined as PASP > 50 mmHg by echo (p = 0.0001 by multivariate 
analysis) [14]. In an overall population of SSc patients, frequency of dyspnea (NHYA class II, 
III, or IV) increased with the levels of velocity of tricuspid regurgitation (VTR) measured by 
echo-Doppler [4]. Accordingly, dyspnea was present in 29.3% of patients with VTR ≤ 2.5 
meters/second, 40.6% with VTR = 2.5 - 3 meters/second, and 72% with VTR > 3 
meters/second.  
One study involving SSc patients with and without PH, 42% of whom had restrictive 
pulmonary function tests, indicated that the presence of PH by echo (PASP > 30 mmHg) was 
significantly associated with abnormal (< 400 m) 6MWT and ΔO2Sat in univariate but not 
multivariate analysis (multiple regression analysis) [16]. 
In another study, baseline PASP by echo was the only parameter that independently correlated 
with maximal oxygen consumption (r = -0.66) and anaerobic threshold (r = -0.52) in stress 
test [33]  
 
Associations with heart structure/function 
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In a SSc population including those with pulmonary fibrosis, right ventricular and right atrial 
enlargement were more frequent in SSc patients with PH by echo PASP ≥ 36-40 mmHg than 
in those without PH (p = 0.03 and p < 0.0001, respectively) [13,25]. PAP by echo-Doppler 
was independently correlated with tricuspid E/A ratio, an index of the right ventricular 
relaxation (r = -0.35, p < 0.003, by multiple regression analysis) [32]. No correlation was 
found between PASP and right ventricular ejection fraction (RVEF) [20] 
 
 
In summary, only an association between the presence of pericardial effusion on echo and 
survival/mortality, was supported with the highest quality study (level A1) [19]. For this 
aspect of the construct validity, echo was rated as validated. 
Although two studies reporting association between echo measurements and 
dyspnea/functional class used the WHO definition of PAH (A1 level) [4,14], analyses 
concerning PASP and functional class included heterogeneous populations of SSc patients 
with and without PAH/PH. For all other aspects of construct validity including associations of 
PASP with survival/mortality, functional capacity, and right heart parameters, only studies 
with a less stringent definition of PH were available (highest quality level A2). Thus, while 
these studies in patients with PH-SSc indicate that echo passes the construct validity criterion 
of the OMERACT filter, it can only be rated as partially validated as long as A1 studies 




Discriminant capacity over time and treatment  
To assess the validity of discriminant capacity over time, longitudinal studies with parallel 
data on RHC and echo at two different time points are required, and for validation of 
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discriminant capacity over treatment it has to be a RCT in addition. However, such trials were 
not available according to our inclusion criteria of the systematic literature review.   
 
Reliability 
One study (quality level B2), including SSc patients with and without PH, showed a low 
intra- and interobserver variability in evaluation of right ventricular ejection fraction and left 
ventricular ejection fraction (range from 3.5% to 5.3%, depending on the parameters) [20]. 
However, there was no study available analyzing intra- or interobserver variability of 
parameters relevant for the assessment of PAH in SSc-patients.  
 
In view of the lack of appropriate longitudinal studies including RCTs it was concluded that 
there are no data available to assess the discrimination criterion. Reliability was analyzed only 




The high number of studies using echo as a diagnostic tool indicates that this method is 
feasible in the clinical assessment of PAH patients. It is ubiquitously available in all centers 
with a cardiology department or a cardiology consultant and the cost-effectiveness for clinical 
studies is reasonable.  
However, it is not possible to obtain PASP values in some patients because of technical 
limitations. Inability to evaluate PASP due to the lack of tricuspid regurgitation and/or due to 
insufficient quality of the images obtained was reported in several studies – Table 5 [4, 13, 
24-25, 29, 32, 34-35, 37-40, 42]. The percentage of patients in whom evaluation of PASP was 
not possible ranged from 3% in the study by Battle et al up to 74% in the study by Candell-
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Reira et al [37, 39]. It should be noted that all studies reported above included SSc patients 
without PAH/PH, in whom the presence of tricuspid regurgitation might be less frequent. Of 
interest, in the study by Denton et al, involving SSc patients considered at high risk of 
PAH/PH, PASP could not be evaluated due to the lack of tricuspid regurgitation in 13 out of 
33 (39%) including 6 out of 21 (29%) patients with PAH/PH by RHC [34].  
In summary, inability to evaluate PASP by echo-Doppler was shown in several studies 
including different populations of SSc patients. All these studies evaluated heterogeneous 
populations of patients with and without PAH/PH or, if including separate analyses of 
PAH/PH patients, were of quality levels below A1 (highest quality level A2) [34,38]. Thus, 
until studies on the ability of echo-Doppler to evaluate PASP exclusively in PAH-SSc (level 





This is the first study addressing the validity of ECHO as an outcome measure in PAH-SSc 
according to a systematic literature review, while recent assessments were based on expert 
opinion only. In addition, one of our main tasks was to consider the quality of available 
studies, which largely depend on the definition of PAH in this patient population. 
Surprisingly, only 5 out of 35 studies (14%) used the current WHO definition of PAH 
(diagnosis confirmed by RHC) and excluded other forms of PH such as left heart disease and 
interstitial lung disease. Based on the analysis of these few studies, a final evaluation 
regarding validity of echo for PAH-SSc could only be completed for the content validity 
criterion of the “OMERACT filter”. In addition, face validity could be evaluated, because this 
criterion does not require studies in PAH-SSc patients. For some other aspects of the 
OMERACT filter, indirect information could be obtained from studies with more 
heterogeneous SSc populations, including SSc patients with and without PAH/PH. Finally, 
the OMERACT criteria “sensitivity to change over time and treatment” could not be 
evaluated at all, because of lack of appropriate data.  
 
Most importantly, the structured literature review and the assessment of identified papers 
according to the OMERACT filter revealed several aspects of echo that need further 
validation in additional studies. This defines a specific research agenda which needs to be 
addressed to allow full validation of echo as an outcome measure in PAH-SSc. This research 




Face validity is the only OMERACT criterion that is fully validated based on the consensus 
of experts who selected echo as an appropriate outcome measure for evaluation of PAH-SSc 
[8] as well as based on its frequent use as an evaluation tool in PAH/PH-SSc studies. There 
are no further studies required.  
 
Echo is not valid with respect to its content validity because measurements of pulmonary 
pressures using echo might be influenced by co-morbidities including left heart dysfunction 
and/or lung fibrosis in SSc patients. There are no further studies required, because available 
data were of sufficient quality (quality level A1) to allow final evaluation of its validation 
status.  
Does the lack of content validity exclude echo as an outcome measure in PAH-SSc? Not 
necessarily, because the lack of specificity of echo could be overcome by excluding relevant 
co-morbidities before SSc patients enter clinical trials. For instance, clinically relevant 
pulmonary fibrosis can be excluded by pulmonary function tests and/or computertomography. 
Indeed, this strategy has already been utilized in many of the randomized controlled trials in 
PAH, where lung fibrosis as documented by decreased FVC was an exclusion criterion [43-
44]. Left heart dysfunction such as valvular diseases can be partially excluded by echo itself, 
although there are controversies whether definite diagnosis of diastolic dysfunction, which is 
more frequent in SSc patients [45], requires invasive testing [46]. Other co-morbidities such 
as pulmonary venous occlusive disease (PVOD) are more difficult to exclude, and it is 
currently unknown if PVOD is of relevant prevalence in PAH-SSc or limited to certain 
patients with a very severe clinical course of pulmonary hypertension [47]. 
 
 The impact scleroderma lung disease  and other comorbidities may have on the correlations 
between echo and RHC in SSc is unclear, however evaluation of RVSP by echo has been 
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found inaccurate in patients with idiopathic pulmonary fibrosis [48]. Therefore, definite 
validation of the criterion and construct validity is required through evaluation of echo versus 
RHC and other outcomes specifically in PAH-SSc. This can be achieved for example by 
cross-sectional studies in PAH-SSc patients performing RHC and other relevant outcome 
measures in parallel with echo (Table 6). Although these data are unpublished, they are 
actually available as part of the baseline measurements in randomized controlled treatment 
trials in PAH. Thus, subanalysis of the baseline measurements in the PAH-SSc population of 
these trials is likely sufficient to fully validate content and construct validity of echo. 
 
Discrimination 
The type of studies required to assess the validity of echo with respect to the discriminant 
capacity over time are longitudinal studies including PAH-SSc patients without treatment and 
parallel echo and RHC evaluations at different time points (Table 6). Again, they are already 
available as unpublished data from the placebo groups of randomized controlled trials with 
RHC and echo performed at baseline and end of study. Although it might be argued that 
placebo-treatment is an intervention and thus patients from the placebo group are not true 
untreated patients, analysis of the PAH-SSc subpopulation of these trials would further 
contribute to the validation of discriminant capacity over time. Similarly, to assess the 
discriminant capacity over treatment, subanalysis of PAH-SSc patients in the verum group of 
these trials is appropriate (Table 6). Validation of reliability of echo in PAH-SSc requires 
comparisons of repeated echo assessments performed within a short time period by the same 
investigator (intra-observer variability) and by two independent investigators (inter-observer 




The validation status of echo with respect to its feasibility was considered unclear since 
evaluation of pulmonary pressures was impossible in a significant proportion of SSc patients 
including PAH/PH-SSc. This was due to the lack of tricuspid regurgitation but also due to 
insufficient quality of echo imaging caused by skin thickening or concomitant severe lung 
disease. Formally, further studies including exclusively PAH-SSc patients are required to 
fully validate feasibility of echo in the evaluation of PAH-SSc. Studies required for full 
validation are cross-sectional analysis of PAH-SSc-patients and are thus similar to studies 
required for other aspects such as criterion and construct validity (Table 6). However, it 
appears rather unlikely that pulmonary pressures can be measured in all patients, because 
some of the limitations such as skin thickening can still be operative in this population. Thus, 
it is likely that echo cannot be used as a single outcome measure and needs to be combined 
with other measures to allow assessment of all patients.  
Many of the studies identified by this systematic literature review focused on PASP, while 
other parameters were rarely considered. However, it needs to be emphasized that other echo 
parameters might be more relevant for certain aspects of PAH-SSc than PASP alone. For 
instance, as shown in patients with severe idiopathic PAH, reduction in PASP may reflect 
disease progression and right-ventricle failure rather than improvement of PAH [49]. In 
addition, although correlations between PASP by echo-Doppler and PASP/mean PAP by 
RHC were statistically significant, they showed low r-values, reflecting the clinical 
experience that PASP by Doppler are not necessarily accurate when compared to directly 
measured pressures in PAH-SSc. Thus, assessment of PASP alone is unlikely to reach full 
validation in PAH-SSc for discriminant capacity of time and treatment. Additional measures 
such as tricuspid annular plane systolic excursion (TAPSE) are promising [50, 51] and should 
be considered for further validation studies in PAH-SSc.  
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In conclusion, this systematic literature analysis demonstrated that echo in PAH-SSc fulfills 
the OMERACT criteria for face validity and partially for criterion and construct validity as 
well as reliability. Other forms of PH such as PH associated with lung fibrosis or left heart 
disease need to be excluded if echo is used as an outcome measure, because the content 
validity criterion is not fulfilled. Validation studies for echo in PAH-SSc should not be 
limited to PASP alone, but should also include other measures such as TAPSE, in particular 
for the assessment of discriminant capacity over time and treatment. Studies required for 
further validation of the OMERACT criteria are largely performed already as part of 
randomized controlled treatment trials in PAH patients. However, subanalyses of PAH-SSc 
with regard to echo as an outcome measure have not been published. Because echo 
pulmonary pressures cannot be measured technically in all patients, echo needs to be 
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